Navigation Links
Celladon Corporation Announces Publication of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure
Date:9/26/2013

SAN DIEGO, Sept. 26, 2013 /PRNewswire/ -- Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced the full three year long-term follow up results from Phase 2a of the CUPID 1 trial in the online publication of Circulation Research. Phase 2a of the CUPID 1 trial investigated Celladon's product candidate MYDICAR in three dose groups for the treatment of advanced heart failure.

"The long term trends observed in the full three years of follow up from the CUPID 1 trial in the MYDICAR high dose group are very encouraging," said Krisztina Zsebo, Ph.D., President and Chief Executive Officer of Celladon Corporation. "The duration of clinical response in the high dose group, coupled with the favorable trend in mortality and lack of safety concerns, leaves us optimistic for future development of MYDICAR."

In the additional two year follow up period of the CUPID 1 trial, the durability of reduced cardiovascular and terminal events previously observed in the MYDICAR high dose cohort at 12 months was maintained. The following recurrent cardiovascular and terminal events were tracked over the three years in all MYDICAR dose groups: myocardial infarction, worsening heart failure, heart failure-related hospitalization, left ventricular assist device (LVAD) placement, heart transplantation, and all-cause death. The risk of pre-specified recurrent cardiovascular events through full three years of follow up was reduced by 82% in the high dose group compared to the placebo group (p=0.048, where p-value is the statistical probability of a result due to chance alone).

In addition, the survival probability over time was higher for patients in all MYDICAR dose groups compared to the placebo group, especially in the high dose group. At three years post-administration, there we
'/>"/>

SOURCE Celladon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Celladon Corporation Named a 2012 Fierce 15 Company by FierceBiotech
2. Celladon Corporation To Present at BioCentury Future Leaders in the Biotech Industry Conference
3. Celladon Corporation and SIRO Clinpharm Announce Presentation at "Statisticians in the Pharmaceutical Industry International Conference"
4. Celladon Corporation Selected as Winner of Red Herrings "Top 100 North America Tech Startup"
5. Celladon Corporation Announces Pre-clinical Study Demonstrating Inhalable MYDICAR Reverses Pulmonary Arterial Hypertension (PAH)
6. Celladon Corporation Announces Appointment of Gregg Alton and Graham Cooper to its Board of Directors
7. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
8. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
9. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
10. Neogen Corporation Announces 2nd Quarter Results Conference Call
11. Luminex Corporation to Present at JP Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... November 2012, the European Union (EU) mandated use of the ... PSUR – responding to the increasing need to understand and ... in many regions, the main objectives of the PBRER are ... analysis of new or emerging information on the risks of ... the potential benefits of a drug; and , ...
(Date:8/18/2014)... 19, 2014 2014 Deep Research ... a professional and in-depth research report on the ... information, including its definition, classification, application, and ... This research covers the international market analysis, including ... analysis covering macroeconomic environment & economic situation analysis. ...
(Date:8/18/2014)... , Aug. 18, 2014   Sterne, Kessler, Goldstein ... in Washington, DC , announced today ... Partes Review (IPR) with the U.S. Patent and ... subsidiary of BioReference Laboratories, Inc. (Nasdaq: BRLI).  These IPR ... licensed by Myriad Genetics, Inc. These patents have been ...
(Date:8/18/2014)... 18, 2014 According to ... By Application (Municipal Wastewater Treatment and Industrial Wastewater ... Multi Tubular), By Configuration (Internal/Submerged and External/Sidestream), and ... MarketsandMarkets, The market for membrane bioreactor systems is ... at a CAGR of 15.28% between 2014 and ...
Breaking Biology Technology:Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3
... Burn rate significantly reduced and Semen Sexing Technology achieves, ... /PRNewswire-FirstCall/ - For nine months ended June 30, 2009, Microbix ... burn rate. The third quarter had a small sales retraction ... rates. The forecast is for continued growth in sales. , ...
... , , NEWTON, Mass., Aug. 6 ... the Company will release second quarter 2009 financial results on ... markets. , , Michael C. Ferrara, President and ... and Chief Accounting Officer, will host a conference call and live ...
... , PALO ALTO, Calif., Aug. 6 Telik, ... $5.7 million, or $0.11 per share, for the second quarter ended June ... per share, for the comparable period in 2008. , , ... expenses were $6.3 million, compared with $11.0 million in the 2008 second ...
Cached Biology Technology:Microbix Sales Grow 22% For Nine Months 2Microbix Sales Grow 22% For Nine Months 3Microbix Sales Grow 22% For Nine Months 4Microbix Sales Grow 22% For Nine Months 5Microfluidics International Corporation to Report Second Quarter 2009 Financial Results on August 11, 2009 2Telik Announces Second Quarter 2009 Financial Results 2Telik Announces Second Quarter 2009 Financial Results 3Telik Announces Second Quarter 2009 Financial Results 4
(Date:8/20/2014)... When a colony of honeybees grows to about 4,000 ... reproductive cycle: the building of a special type of ... team of experts from the Department of Neurobiology and ... what starts the reproductive cycle of honeybee colonies. The ... The Science of Nature . , Reproduction isn,t ...
(Date:8/19/2014)... be made to decrease China,s increasing caesarean section rate, ... BJOG: An International Journal of Obstetrics and Gynaecology ... caesarean delivery rates in the world. Of 16 million ... Although the exact rate is not known, the current ... total caesarean rates ranging from 36% to 58%. However, ...
(Date:8/19/2014)... lemur. It,s not an African Bush Baby or even a ... downright "cool" primate from Southeast Asia. , "It,s really not ... Brown, curator-in-charge at the University of Kansas, Biodiversity Institute. "A ... body; a long tail with a furry tuft at the ... a bit like the disks on the digits of tree ...
Breaking Biology News(10 mins):Worker bees 'know' when to invest in their reproductive future 2Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3
... DENVER Researchers have linked a variant in the ... chronic obstructive pulmonary disease (COPD) in Caucasian men. The ... Normative Aging Study, a multidisciplinary study of aging that ... presented at the ATS 2011 International Conference. "Our ...
... the process of converting the genetic information encoded in ... protein or any of several types of RNA. Scientists ... different physiological processes throughout the body are robustly pre-determined ... new study by researchers from the University of California, ...
... Most people who have had the experience of having ... the animals can "recognize" us. They seem to recognize our ... they respond to us differently from other people. , Actually, ... shown that domesticated animals, such as honey bees, chickens, pigeons, ...
Cached Biology News:Gene variant linked with development of COPD in men 2Plasticity of hormonal response permits rapid gene expression reprogramming 2I know you, bad guy! 2I know you, bad guy! 3
The Discovery Series PDQuest 2-D analysis software is used for imaging, analyzing, and databasing two-dimensional electrophoretic gels. The 10-user network license entitles ten users to access data f...
Mouse monoclonal antibody raised against a partial recombinant NR4A2. NCBI Entrez Gene ID = NR4A2...
... Polymorphic DNA Technologies also offers a DNA ... of templates including plasmids, PCR products, BACs, ... customer-provided templates such as purified plasmids or ... liquid handling robotics optimized for automated reaction ...
... NightOWL is a dedicated imaging system ... size. Equipped with a very sensitive camera ... or plants in tumor research, infectious disease ... Western blots. NightOWL is the only imager ...
Biology Products: